Training Hematology and Oncology Fellows in Clinical Research
Training Hematology and Oncology Fellows in Clinical Research
批准号:
10434663
负责人:
Claire F. Verschraegen
金额:
$16.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-01 至 2025-06-30
中文摘要
项目总结
俄亥俄州立大学临床T32博士后培训项目的目标是:
临床研究血液学和肿瘤学研究员“是提供最先进的临床研究培训
经验,特别是血液学和肿瘤学博士后研究员,拥有医学博士、博士学位或同等学历
具有坚定致力于以病人为中心的癌症研究的学位。压倒一切的目标是
该培训计划是为俄亥俄州立大学血液学和肿瘤学分部的血液学和肿瘤学研究员做准备
面向患者的临床和转化性癌症研究的学术生涯的医学肿瘤学。
癌症治疗和预防的进步需要强有力的合作努力,以及以患者为中心的医生
研究人员为实现这一目标提供了与内科科学家和基础科学家的关键联系。最近的
科学发现的爆炸性增长和癌症临床试验的日益复杂,特别是阶段
I/II研究新的治疗药物和方案,使血液学/肿瘤学的受训人员成为当务之急
通过适当的指导获得适当的培训,为他们从事临床和翻译工作做好准备
调查。这项T32计划将通过提供以下方面的培训,帮助学员为富有成效的学术生涯做准备
智力严谨的课程,资深教职员工强有力的指导和支持,保护学术时间
团契期间的培训,在开发和撰写临床研究和研究论文方面的“实践”经验,
并有充足的机会通过赞助的校外项目和研讨会来增强他们在OSU的经验
由NCI或其他专业学术组织,如ASCO和ASH。参加会议的成员
由2名项目主任、协调委员会成员、咨询委员会成员、主要成员组成
导师和特约教员,他们是根据他们以前成功指导的记录来选择的
以及他们对临床和转化性研究的承诺。T32研究员将承诺两年
训练有素。OSUCCC的优势,主要是在癌症预防和实验领域
治疗,是我们取得计划成功的完美环境。我们的T32提案旨在促进和
确保奖学金学员的发展,我们将对他们进行培训,以承担学术临床研究职位
作为毕业时的教职员工。T32计划旨在帮助学员成为
独立的临床和翻译研究人员。学员将接受各种形式的强制性选修培训
设置,包括获得一个或两个硕士学位的机会;它们将被要求创建
研究人员发起了临床研究,并将在培训期间开始实施;他们将被要求申请
通过同行评审的资助机制为他们自己的研究提供资金;他们将获得机会
在全国范围内与NCI和肿瘤学专业组织建立网络。OSUCCC也深深地致力于
培训妇女和代表不足的种族和民族群体的成员从事学术职业
继续努力招聘和培训女性和代表性不足的少数群体研究员。
英文摘要
PROJECT SUMMARY
The objective of this Ohio State University postdoctoral clinical T32 training program entitled: “Training
Hematology and Oncology Fellows in Clinical Research” is to provide a state of the art clinical research training
experience, specifically for postdoctoral fellows in Hematology and Oncology with an M.D., D.O., or equivalent
degree who have demonstrated a firm commitment to patient oriented cancer research. The overriding goal of
this training program is to prepare Hematology and Oncology fellows in the OSU Divisions of Hematology and
Medical Oncology for academic careers in patient oriented clinical and translational cancer investigation.
Progress in cancer therapy and prevention requires strong collaborative efforts, and patient oriented physician
investigators provide a critical link with physician-scientists and basic scientists toward this goal. The recent
explosive growth of scientific discoveries and the increasing complexity of cancer clinical trials, particularly phase
I/II studies of novel therapeutic agents and regimens, make it imperative that trainees in Hematology/Oncology
acquire the proper training through appropriate mentoring, to prepare them for careers in clinical and translational
investigation. This T32 program will prepare fellowship trainees for productive academic careers by providing an
intellectually rigorous curriculum, strong mentoring and support from senior faculty, protected time for academic
training during fellowship, “hands on” experience in developing and writing clinical studies and research papers,
and ample opportunities to enhance their OSU experience with extramural programs and workshops sponsored
by the NCI or other professional academic organizations such as ASCO and ASH. The participating members
consist of the 2 Program Directors, Coordinating Committee members, Advisory Committee members, primary
mentors, and contributing faculty, who were chosen based on their prior track record of successful mentoring
and their demonstrated commitment to clinical and translational research. T32 fellows will commit for two years
of training. The strengths of the OSUCCC, primarily in the fields of cancer prevention and experimental
therapeutics, is the perfect environment to our planned success. Our T32 proposal is designed to foster and
ensure the development of fellowship trainees, who we will train to assume academic clinical research positions
as faculty members upon graduation. The T32 program is engineered to empower trainees to become
independent clinical and translational investigators. Trainees will have mandatory an elective training in various
settings, including the opportunity to obtain one or two master degrees; they will be required to create an
investigator initiated clinical study and will start its implementation during training; they will be required to apply
for funding for their own study through peer reviewed grant mechanisms; and they will be offered the opportunity
to network nationally with the NCI and oncology professional organizations. OSUCCC is also deeply committed
to training women and members of underrepresented racial and ethnic groups for academic careers as shown
in continuous efforts to recruit and train female and underrepresented minority fellows.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training Hematology and Oncology Fellows in Clinical Research
-
批准号:10675683
-
项目类别:
-
资助金额:$17.4万
-
财政年份:2020
-
负责人:Claire F. Verschraegen
-
依托单位:
Protocol Specific Research Support
-
批准号:8180663
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2010
-
负责人:Claire F. Verschraegen
-
依托单位:
CLINICAL PROTOCOL, DATA MANAGEMENT, AND INFORMATICS
-
批准号:7127433
-
项目类别:
-
资助金额:$12.21万
-
财政年份:2005
-
负责人:Claire F. Verschraegen
-
依托单位:
NM Minority Based Community Clinical Oncology Program
-
批准号:7122049
-
项目类别:
-
资助金额:$47.64万
-
财政年份:2000
-
负责人:Claire F. Verschraegen
-
依托单位:
New Mexico Minority-Based Community Clinical Oncology Program
-
批准号:7643448
-
项目类别:
-
资助金额:$78.98万
-
财政年份:2000
-
负责人:Claire F. Verschraegen
-
依托单位:
NM Minority Based Community Clinical Oncology Program
-
批准号:7266274
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2000
-
负责人:Claire F. Verschraegen
-
依托单位:
New Mexico Minority-Based Community Clinical Oncology Program
-
批准号:7473432
-
项目类别:
-
资助金额:$65.27万
-
财政年份:2000
-
负责人:Claire F. Verschraegen
-
依托单位:
ORAL 9 NITROCAMPTOTHECIN IN PATIENTS WITH ADVANCED MULLERIAN CANCER
-
批准号:6309258
-
项目类别:
-
资助金额:$1.51万
-
财政年份:1999
-
负责人:Claire F. Verschraegen
-
依托单位:
ORAL 9 NITROCAMPTOTHECIN IN PATIENTS WITH ADVANCED MULLERIAN CANCER
-
批准号:6121116
-
项目类别:
-
资助金额:$1.51万
-
财政年份:1998
-
负责人:Claire F. Verschraegen
-
依托单位:
9 NITRO 20 CAMPTOTHECIN PROPIONATE IN PTS W/ ADVANCED MALIGNANCIES
-
批准号:6265672
-
项目类别:
-
资助金额:$1.11万
-
财政年份:1998
-
负责人:Claire F. Verschraegen
-
依托单位:
ORAL 9NITROCAMPTOTHECIN IN PATIENTS WITH ADVANCED MULLERIAN CANCER
-
批准号:6252276
-
项目类别:
-
资助金额:$1.67万
-
财政年份:1997
-
负责人:Claire F. Verschraegen
-
依托单位:
ORAL 9NITROCAMPTOTHECIN IN PATIENTS WITH ADVANCED MULLERIAN CANCER
-
批准号:6281686
-
项目类别:
-
资助金额:$1.36万
-
财政年份:1997
-
负责人:Claire F. Verschraegen
-
依托单位:
TREATMENT OF OVARIAN CANCER WITH SB75, A LHRH ANTAGONIST
-
批准号:2443300
-
项目类别:
-
资助金额:$13.04万
-
财政年份:1996
-
负责人:Claire F. Verschraegen
-
依托单位:
TREATMENT OF OVARIAN CANCER WITH SB75, A LHRH ANTAGONIST
-
批准号:2115491
-
项目类别:
-
资助金额:$13.74万
-
财政年份:1996
-
负责人:Claire F. Verschraegen
-
依托单位:
9 NITRO 20 CAMPTOTHECIN PROPIONATE IN PATIENTS W/ ADVANCED MALIGNANCIES
-
批准号:6309236
-
项目类别:
-
资助金额:$1.11万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
CLINICAL PROTOCOL, DATA MANAGEMENT, AND INFORMATICS
-
批准号:7560655
-
项目类别:
-
资助金额:$18.23万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
Protocol Specific Research Support
-
批准号:8545095
-
项目类别:
-
资助金额:$4.67万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
CLINICAL PROTOCOL, DATA MANAGEMENT, AND INFORMATICS
-
批准号:7675234
-
项目类别:
-
资助金额:$18.51万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
CLINICAL PROTOCOL, DATA MANAGEMENT, AND INFORMATICS
-
批准号:7560637
-
项目类别:
-
资助金额:$12.51万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
Protocol Specific Research Support
-
批准号:8545091
-
项目类别:
-
资助金额:$0.78万
-
财政年份:--
-
负责人:Claire F. Verschraegen
-
依托单位:
海外基金